Picture week three of a launch. A rep has finally got time with a specialist who has seen every rep in the territory this month. The door is open for maybe five minutes. The specialist doesn't want the visual aid. She asks one question: "Which of my patients is this actually for?"
What happens in the next ten seconds decides whether there is a second meeting. If the answer comes back precise, confident and on label, the conversation opens up. If the rep hesitates on the core argument or offers something close but not quite right, the specialist has learned what she needed to know. Not about the product. About the rep.
Our view, after 100 programs with field forces, is that every launch has a short list of facts that must be known cold, and that most launch readiness plans never define that list, never certify people on it and never tell managers who is missing what. This piece is about fixing all three.
Short meetings are decided by the first two questions
Access to specialists has become harder. Many physicians see fewer reps, for less time, and some only through a scheduled slot or a remote call. The long detailing conversation with a generous, curious prescriber still happens, but it is not the one to plan for.
The one to plan for is short. The specialist has a clinic running late, knows the disease better than the rep does and has already heard something about the product, often from a KOL, a congress session or a competitor's rep. In that setting, the first questions are rarely open-ended. They're tests. Who is the patient? What did the trial actually show? What about safety? How does it compare with what I use today? Can my patients get it?
A rep who answers those crisply earns the right to talk about everything else. A rep who fumbles one of them rarely gets to the rest of the story, however good the rest of the story is.
The five-minute argument is won or lost before the rep walks in. It is won in the weeks when nobody is watching.
Not all launch knowledge is equal
A typical launch curriculum treats everything as roughly equally important. The disease module, the mechanism animation, the trial deep dive, the competitor section, the access briefing and the objection handlers all get their slot, their slides and their end-of-module quiz.
That's a reasonable way to teach. It's a poor way to decide what the field must be certified on. For readiness purposes, launch knowledge splits into two very different kinds.
There's knowledge the rep should understand: the disease pathway, the history of the class, the full trial design, the nuances of each subgroup. This helps them follow a scientific conversation and ask good questions. It is fine if it lives partly in the materials and gets looked up when needed.
And there's knowledge the rep must state without hesitation: a short set of facts where a pause, an approximation or a mistake costs credibility on the spot. That's the know-cold list. In our experience it rarely runs to more than a few dozen items, and it usually falls into five groups.
1. The indication and the patient who fits it
Not the full label paragraph, but the rep's version of it: which patient, at which stage, after or alongside which treatments. This is where reps most often drift, usually by broadening the patient profile in the direction of hope. It's also where drifting creates compliance risk as well as credibility risk.
2. Two or three headline results, with the exact numbers
The primary endpoint, the result and the comparator. One or two key secondary endpoints the brand team has chosen to lead with. The exact figures matter. "About a third fewer exacerbations" and the real number are not interchangeable when the person across the desk has read the paper.
3. The key safety messages
The most common adverse events, the warnings and contraindications, and any monitoring requirement. Specialists often ask about safety second, and a rep who is vague here tends to lose the room quickly. This is also the area where medical and compliance teams most want certainty.
4. The one-line answer to the obvious comparison
Every launch has a "how is this different from what I use now?" question. The approved answer is usually carefully worded, on label and supported by specific data. Reps need to know it word-perfect in substance, and know which claims they may not make.
5. The access and dosing facts that turn interest into a first prescription
Formulary status in the account, the reimbursement route, the starting dose, the administration and any practical step a clinic must take. A physician who is convinced but can't see how to get the patient started often just doesn't bother.
How to build the list in one working session
The know-cold list is not a content project. It's a decision, and it should be taken by the people who own the message. We'd suggest one working session, before the kickoff agenda is fixed, with brand, medical, a sales lead or two and someone from training.
Start from the questions specialists will actually ask in the first minutes. Sales will have the best instinct here, from ride-alongs, advisory boards and the last launch. For each question, agree the approved answer, then apply a single test: if a rep hesitated or got this slightly wrong, would a specialist think less of them? If yes, it goes on the list. If not, it's "should understand" and stays in the materials.
Then turn every item into two or three questions with plausible wrong answers. The wrong options matter as much as the right one. They should reflect the mistakes reps really make: the neighbouring number, last year's comparator, the broader patient population, the adverse event that belongs to a different product in the class. Run the bank through MLR as a bank, re-review it when the label or evidence changes, and you have a reusable certification instrument for the whole launch.
Certify the list, not the course
Most launch training reports completion. Completion tells you who opened the module and reached the end. It says nothing about whether they can answer the specialist's second question on a Tuesday morning three weeks later.
Certification on the know-cold list is a different kind of measure. It asks, for each person and each critical fact, whether they answer it correctly and repeatedly within the assessment. And reliably is the key word. Getting a question right once proves very little: with four options, a quarter of guesses are right, and a rep who half-remembers will get lucky more often than that.
We use a strict rule. A critical gap only counts as closed when the same person answers 5 of 5 later check questions on the same concept correctly. It's a demanding standard, and that's intended. But be clear about what it is: an assessment rule, not a guarantee. It makes a lucky guess much less likely than a single right answer does, without ruling it out, and it tells you the rep can pick the right answer on a screen. It does not prove they will say it well, or at all, in front of a specialist. That part still needs a manager in the room or on the call.
Know it cold, or know when to stop
The list has a boundary, and the boundary matters as much as the list. Some facts a rep must recall without help: the indicated patient, the headline results, the key safety messages, the approved comparison, the access route. Other questions should never be answered from memory at all. An off-label use, a patient who sits outside the trial population, a specific adverse event report, a dosing question in an unusual clinical situation: these belong to Medical Information or the MSL, and the right answer is a clean handover, not a confident improvisation.
So every item on the list should carry two things: the approved source it comes from, and the point where the rep stops and escalates. Certify both. A rep who knows the primary endpoint cold but doesn't know when a question has crossed into Medical territory is a compliance risk, however polished the rest of the call.
A fair objection is that this turns reps into reciters. Nobody wants a field force that parrots numbers; the best specialist conversations are genuine exchanges, led by the physician's own patients and questions. We agree, and that's exactly why the list is short. Knowing a few dozen facts without hesitation is what frees a rep to listen, follow the conversation and think. The rep who has to search their memory for the primary endpoint isn't really listening to anything else.
The errors that cost the most are invisible until you measure them
When we look across our case library, the most important gaps are rarely the ones anyone expected. They're not missing knowledge, where the rep simply hasn't learned something. They're wrong knowledge, where the rep has confidently learned the opposite.
In one global immunology kickoff with 1,330 players across four franchise games, a misconception about the product's mechanism was held by 125 reps. It was invisible in the kickoff, because a room full of people nodding at a mechanism animation looks exactly like a room full of people who understood it. It only became visible when every person answered the same question. And once visible, it barely moved with repetition.
That pattern isn't unusual. In one in five of the example questions we tracked, fewer than 20% of the people who were wrong corrected it through repetition alone; some of those were never retested, so not all are proven misconceptions. The ones that are tend to be precisely the kind of error that surfaces in the first minute with a specialist.
A second example, from an APAC MedTech vascular program: 110 of 345 players could not state the three factors behind device choice in complex anatomy. For a MedTech rep, that's a core know-cold item. It's the question an interventional specialist will ask to decide whether the rep is worth having in the lab.
Neither of these would have shown up in completion data. Both showed up the moment each person was asked, individually, to answer.
Give every manager their team's list
Measurement only pays off if it reaches the people who can act on it. At the end of a certification window, each first-line manager should get a short, specific view: which of their people still miss which critical facts, and whether the gap looks like forgetting (closing with repetition) or a misconception (not moving).
That changes what a ride-along is for. Instead of a generic observation of three calls, the manager arrives knowing that one rep still broadens the patient profile and another can't give the approved comparison answer. The coaching conversation in the car takes five minutes and targets the exact point. It also changes the cycle meeting: the regional agenda can spend twenty minutes on the two items most of the region still misses, instead of replaying the kickoff.
Managers are often wary of this kind of data, and it's worth addressing directly. The point isn't a league table or a performance file. It's a coaching tool, used between the manager and the rep. Programs that frame it that way tend to get far more honest participation than those that don't.
Where to start before your next launch meeting
Take one question to your next launch team meeting: if a specialist gave each of our reps five minutes tomorrow, which five questions would decide the meeting, and how many of our people could answer all five correctly right now?
If nobody in the room can answer the second half, that's the gap to close first. Define the list, certify every person on it with a strict rule, and put the results in managers' hands while there's still time to coach.
At Atrivity, this is how we build critical questions and certification into launch programs, with one-minute challenges against real colleagues and Gap Fixing that sends each rep the fix for their own mistakes. But the discipline matters more than the tool. The five-minute argument is won before the meeting. Make sure every rep walks in knowing it cold.